{"entity":{"id":"isabelle-ray-coquard","kind":"person","name":"Isabelle Ray-Coquard","aka":[],"tldr":"Led PAOLA-1, which showed olaparib plus bevacizumab helps women with HRD-positive ovarian cancer beyond BRCA carriers.","summary":"Isabelle Ray-Coquard was principal investigator of PAOLA-1, the ENGOT/GINECO trial showing maintenance olaparib added to bevacizumab improves progression-free and overall survival in first-line advanced ovarian cancer with homologous recombination deficiency, which made HRD testing a standard part of ovarian cancer care. She leads the French GINECO group and international networks for rare gynaecological cancers.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ray-Coquard%20I%5BAuthor%5D%20ovarian%20PAOLA"}],"tags":["ovarian","parp","hrd"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":["parp-inhibitor","hrd-testing","antiangiogenic"],"targets":["parp","brca","vegf"],"drugs":["olaparib"],"companies":["arcagy-gineco"],"institutions":["centre-leon-berard"],"pathways":[],"terms":[],"trials":["paola-1"],"people":[],"bottlenecks":[],"keyPapers":["paper-paola-1-nejm-2019"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology, Centre Léon Bérard and Université Claude Bernard Lyon 1; President, GINECO","institutionId":"centre-leon-berard","specialisms":["Ovarian cancer","Rare gynaecological tumours","PARP inhibitor combinations","Sarcoma"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ray-Coquard%20I%5BAuthor%5D%20ovarian%20PAOLA"}],"papers":[{"title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer (PAOLA-1)","journal":"NEJM","year":2019,"doi":"10.1056/NEJMoa1911361"},{"title":"Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial","journal":"Annals of Oncology","year":2023,"doi":"10.1016/j.annonc.2023.05.005"}]},"route":"/people/isabelle-ray-coquard/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"hrd-testing","kind":"technology","name":"HRD & BRCA testing","route":"/technologies/hrd-testing/"},{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"}],"target":[{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/"},{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"},{"id":"vegf","kind":"target","name":"VEGF / VEGFR","route":"/targets/vegf/"}],"drug":[{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"}],"company":[{"id":"arcagy-gineco","kind":"company","name":"ARCAGY-GINECO","route":"/companies/arcagy-gineco/"}],"institution":[{"id":"centre-leon-berard","kind":"institution","name":"Centre Léon Bérard","route":"/institutions/centre-leon-berard/"}],"trial":[{"id":"paola-1","kind":"trial","name":"PAOLA-1 / ENGOT-ov25","route":"/trials/paola-1/"}],"paper":[{"id":"paper-paola-1-nejm-2019","kind":"paper","name":"PAOLA-1: olaparib added to bevacizumab maintenance in newly diagnosed ovarian cancer, with benefit confined to HRD-positive tumours","route":"/key-papers/paper-paola-1-nejm-2019/"}]}}